# Safety, Tolerability and Antimalarial Activity of Single Doses of OZ439 and PQP

> **NCT03542149** · PHASE1 · COMPLETED · sponsor: **Medicines for Malaria Venture** · enrollment: 24 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** 480 mg Piperaquine phosphate
- **DRUG:** 640 mg Piperaquine phosphate
- **DRUG:** 200 mg OZ 439
- **DRUG:** 400 mg OZ 439
- **DRUG:** 800 mg OZ 439
- **DRUG:** 960 mg PQP
- **DRUG:** 320 mg PQP

## Key facts

- **NCT ID:** NCT03542149
- **Lead sponsor:** Medicines for Malaria Venture
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-23
- **Primary completion:** 2019-04-19
- **Final completion:** 2019-04-19
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-05-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03542149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03542149, "Safety, Tolerability and Antimalarial Activity of Single Doses of OZ439 and PQP". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT03542149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*